NEW YORK (GenomeWeb) – UgenTec announced today a partnership to develop artificially intelligent software to support interpretation of molecular test results for MDxHealth's ConfirmMDx and SelectMDx for prostate cancer tests.

MDxHealth's SelectMDx test is a liquid biopsy test that identifies patients with an increased risk for clinically significant prostate cancer. The firm's ConfirmMDx is a tissue biopsy test that allows patients to forgo unnecessary repeat biopsy procedures.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

May
22
Sponsored by
Thermo Fisher Scientific

In this webinar, the third in the “New Frontiers in Liquid Biopsy Research” series, Dr. Liya Xu of the University of Southern California Michelson Center for Convergent Biosciences will discuss her team’s work using liquid biopsy technology for breast cancer research.

Jun
14

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Jun
19

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.